BioPharma Credit PLC

Equities

BPCP

GB00BDGKMY29

Closed End Funds

Market Closed - London S.E. 11:35:25 2024-04-26 am EDT 5-day change 1st Jan Change
0.878 USD +0.23% Intraday chart for BioPharma Credit PLC +0.23% +4.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals MT
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals AN
BioPharma Credit PLC Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioPharma Credit net asset value ticks up but total payout lower AN
BioPharma Credit Board, Investment Manager Propose Changes to Discount Control Mechanism MT
BioPharma Credit Logs Lower FY23 Net Income Return on Ordinary Activities MT
Tranche Update on BioPharma Credit PLC's Equity Buyback Plan announced on May 31, 2023. CI
Biopharma Credit plc Declares Interim Dividend in Respect of the Financial Period Ending 31 March 2024, Payable on 30 April 2024 CI
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase AN
Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen MT
BioPharma Credit PLC Declares Interim Special Dividend in Respect of the Financial Period Ending 31 December 2023, Payable on 15 March 2024 CI
BioPharma Credit PLC Declares Ordinary Interim Dividend in Respect of the Financial Period Ending 31 December 2023, Payable on 15 March 2024 CI
Jefferies Downgrades BioPharma Credit to Hold from Buy MT
Jefferies cuts BioPharma Credit to 'hold' AN
Barratt takes over Redrow in GBP2.5 billion deal AN
BioPharma Credit to receive partial prepayment of loan AN
BioPharma Credit to fund LumiraDx ahead of acquisition by Roche AN
BioPharma Credit notes loan agreement amendment by LumiraDx AN
BioPharma Credit notes AbbVie takeover of investee ImmunoGen AN
Biopharma Credit plc Declares Special Dividend in Respect of the Financial Period Ended 30 September 2023, Payable on 5 January 2024 CI
BioPharma Credit PLC Declares Interim Dividend in Respect of the Financial Period Ended 30 September 2023, Payable on 5 January 2024 CI
BioPharma Credit says liquidity covenant in loan deal waived AN
BioPharma Credit PLC Reports Earnings Results for the Half Year Ended June 30, 2023 CI
BioPharma Credit hails "attractive pipeline" and backs dividend target AN
BioPharma Credit PLC Provides Dividend Guidance for the Full Year Ending December 31, 2023 CI
Chart BioPharma Credit PLC
More charts
BioPharma Credit PLC is a United Kingdom-based closed-ended investment company. The principal activity of the Company is to invest in interest-bearing debt assets with a contractual right to future cash flows derived from royalties or sales of approved life sciences products. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve its investment objective predominantly through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt and credit linked notes. Its diversified portfolio is primarily secured by cash flows derived from sales of approved life sciences products. The Company holds a majority of its investments through its financing subsidiary, BPCR Limited Partnership. Its investment manager is Pharmakon Advisors L.P.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.876
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. BPCP Stock
  4. News BioPharma Credit PLC
  5. BioPharma Credit : Earnings Flash (BPCR.L) BIOPHARMA CREDIT Reports H1 Revenue $74.7M